Mark R. Bamforth

Exec. Chair and CEO, Arranta Bio

Mark Bamforth founded Arranta Bio to build the best-in-class microbiome CDMO, in May 2019. Arranta has process development and early clinical manufacturing in Florida and a late-stage manufacturing facility in Massachusetts. Previously, Bamforth founded Brammer Bio, a best-in-class viral vector contract development and manufacturing organization (CDMO) for cell and gene therapies. Brammer’s team grew from 110 in 2016 to over 600 in Florida and Massachusetts, at the time of its acquisition by Thermo Fisher Scientific in April 2019.

In 2010, Bamforth founded a biologics CDMO, Gallus BioPharmaceuticals, and acquired a world-class facility and team in St. Louis, MO, with a commercial supply agreement with Janssen. Gallus tripled through organic growth and merging with Laureate Biopharma. Gallus was sold to DPx Holdings B.V. in 2014.

Bamforth previously spent 22 years in the UK and USA at Genzyme, latterly running a global manufacturing operation and a pharmaceutical CMO business and serving as a corporate officer for 9 years. He began his career as a petroleum engineer exploring for North Sea oil with Britoil, then as a chemical engineer in the whisky industry with Whitbread. Bamforth serves on the boards of Avid Bioservices, Continuus Pharma, Pneumagen, Enterobiotix, MassBio, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University. and an MBA from Henley Management College.